EUVIMEDEUVIMED entdecken
Crossref

Peripheral expression of brain-penetrant progranulin rescues pathologies in mouse models of frontotemporal lobar degeneration

Marvin Reich iD, Matthew J Simon iD, Beate Polke, Iñaki Paris iD, Georg Werner iD, Christian Schrader, Lena Spieth, Sonnet S Davis iD, Sophie Robinson iD, Gabrielly Lunkes de Melo iD, Lennart Schlaphoff iD, Katrin Buschmann und 15 weitere

Science Translational Medicine · 05.06.2024 · 16 (750)

DOI: 10.1126/scitranslmed.adj7308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 05.06.2024. Verfasst von Marvin Reich und 26 weiteren Autor:innen. Beteiligte Einrichtung: German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany. Hauptthemen laut MEDLINE: Brain, Dependovirus, Disease Models, Animal, Frontotemporal Lobar Degeneration. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 88 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Progranulin (PGRN) haploinsufficiency is a major risk factor for frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43) pathology (FTLD- GRN ). Multiple therapeutic strategies are in clinical development to restore PGRN in the CNS, including gene therapy. However, a limitation of current gene therapy approaches aimed to alleviate FTLD-associated pathologies may be their inefficient brain exposure and biodistribution. We therefore developed an adeno-associated virus (AAV) targeting the liver (L) to achieve sustained peripheral expression of a transferrin receptor (TfR) binding, brain-penetrant (b) PGRN variant [AAV(L):bPGRN] in two mouse models of FTLD- GRN , namely, Grn knockout and GrnxTmem106b double knockout mice. This therapeutic strategy avoids potential safety and biodistribution issues of CNS-administered AAVs and maintains sustained concentrations of PGRN in the brain after a single dose. AAV(L):bPGRN treatment reduced several FTLD- GRN –associated pathologies including severe motor function deficits, aberrant TDP-43 phosphorylation, dysfunctional protein degradation, lipid metabolism, gliosis, and neurodegeneration in the brain. The potential translatability of our findings was tested in an in vitro model using cocultured human induced pluripotent stem cell (hiPSC)–derived microglia lacking PGRN and TMEM106B and wild-type hiPSC-derived neurons. As in mice, aberrant TDP-43, lysosomal dysfunction, and neuronal loss were ameliorated after treatment with exogenous TfR-binding protein transport vehicle fused to PGRN (PTV:PGRN). Together, our studies suggest that peripherally administered brain-penetrant PGRN replacement strategies ameliorate FTLD- GRN relevant phenotypes including TDP-43 pathology, neurodegeneration, and behavioral deficits. Our data provide preclinical proof of concept for the use of this AAV platform for treatment of FTLD- GRN and potentially other CNS disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrainDependovirusDisease Models, AnimalFrontotemporal Lobar DegenerationMice, KnockoutProgranulinsAnimalsHumansMiceDNA-Binding ProteinsGenetic TherapyPhosphorylationReceptors, Transferrin

Substanzen

DNA-Binding ProteinsProgranulinsReceptors, TransferrinGrn protein, mouse

Autor:innen und Institutionen

  • German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.
  • Graduate School of Systemic Neurosciences (GSN), LMU Munich, 82152 Planegg, Germany.
  • Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, 81377 Munich, Germany.
  • Denali Therapeutics Inc., South San Francisco, CA 94080, USA.
  • Metabolic Biochemistry, Biomedical Centre (BMC), Faculty of Medicine, LMU Munich, 81377 Munich, Germany.
  • Institute of Neuronal Cell Biology, Technical University Munich, 80802 Munich, Germany.

ORCID-Profile: Marvin Reich, Matthew J Simon, Iñaki Paris, Georg Werner, Sonnet S Davis, Sophie Robinson, Gabrielly Lunkes de Melo, Lennart Schlaphoff, Stefan Berghoff, Todd Logan, Lis de Weerd, Dieter Edbauer, Jung H Suh, Thomas Sandmann, Mihalis S Kariolis, Sarah L DeVos, Joseph W Lewcock, Dominik Paquet, Anja Capell, Gilbert Di Paolo, Christian Haass

Zitieren

APA

Reich, M., Simon, M. J., Polke, B., Paris, I., Werner, G., Schrader, C., Spieth, L., Davis, S. S., Robinson, S., de Melo, G. L., Schlaphoff, L., Buschmann, K., Berghoff, S., Logan, T., Nuscher, B., de Weerd, L., Edbauer, D., Simons, M., Suh, J. H., …, & Haass, C. (2024). Peripheral expression of brain-penetrant progranulin rescues pathologies in mouse models of frontotemporal lobar degeneration. Science Translational Medicine, 16(750). https://doi.org/10.1126/scitranslmed.adj7308

Vancouver

Reich M, Simon MJ, Polke B, Paris I, Werner G, Schrader C, et al. Peripheral expression of brain-penetrant progranulin rescues pathologies in mouse models of frontotemporal lobar degeneration. Science Translational Medicine. 2024;16(750). doi:10.1126/scitranslmed.adj7308

BibTeX
@article{Reich2024,
  author = {Reich, Marvin and Simon, Matthew J and Polke, Beate and Paris, Iñaki and Werner, Georg and Schrader, Christian and Spieth, Lena and Davis, Sonnet S and Robinson, Sophie and de Melo, Gabrielly Lunkes and Schlaphoff, Lennart and Buschmann, Katrin and Berghoff, Stefan and Logan, Todd and Nuscher, Brigitte and de Weerd, Lis and Edbauer, Dieter and Simons, Mikael and Suh, Jung H and Sandmann, Thomas and Kariolis, Mihalis S and DeVos, Sarah L and Lewcock, Joseph W and Paquet, Dominik and Capell, Anja and Di Paolo, Gilbert and Haass, Christian},
  title = {Peripheral expression of brain-penetrant progranulin rescues pathologies in mouse models of frontotemporal lobar degeneration},
  journal = {Science Translational Medicine},
  year = {2024},
  volume = {16},
  number = {750},
  doi = {10.1126/scitranslmed.adj7308}
}
Kostenlos starten →